1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Fendrix [Hepatitis B (rDNA) Vaccine (adjuvanted, adsorbed)] is GSK’s monovalent vaccine that protects patients against acute and chronic infections caused by all identified strains of HBV. Since 2005, Fendrix has been approved in the 5EU for the active immunization of patients =15 years of age with renal insufficiency (i.e., pre-hemodialysis and hemodialysis).

Scope

- Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fendrix including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fendrix for top eight countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, UK, Japan and Canada.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fendrix performance
- Obtain sales forecast for Fendrix from 2012-2022 in the top eight countries (the US, France, Germany, Italy, Spain, UK, Japan and Canada).

Table Of Contents

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Overview 12
3.2 Etiology and Pathophysiology 13
3.2.1 Etiology 13
3.2.2 Pathophysiology 16
3.3 Symptoms 18
3.4 Prognosis 20
4 Vaccination Recommendations and Coverage Rates 21
4.1 Overview 21
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 25
6 Fendrix 28
6.1 Overview 28
6.2 Immunogenicity 29
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 47
7.3 Methodology 50
7.4 Forecasting Methodology 50
7.4.1 Patient Populations Targeted for Vaccination 51
7.4.2 Vaccination Coverage Rates 54
7.4.3 Vaccinated Patients 55
7.4.4 Regulatory Approval vs. Advisory Committee Recommendation 55
7.4.5 General Pricing Assumptions 56
7.4.6 Individual Vaccine Assumptions 57
7.5 Physicians and Specialists Included in this Study 58
7.5.1 Interviews of Key Opinion Leaders (KOLs) 58
7.5.2 Online Survey of High-Prescribing Physicians (non-KOLs) 60
7.6 About the Authors 61
7.6.1 Analyst 61
7.6.2 Therapy Area Director 61
7.6.3 Global Head of Healthcare 62
7.7 About GlobalData 63
7.8 Disclaimer 63

1.1 List of Tables

Table 1: Modes of HBV Transmission 17
Table 2: HBV Serological Markers and Test Interpretations 18
Table 3: Symptoms of HBV Infection 19
Table 4: HBV Vaccination Advisory Committees by Country 22
Table 5: HBV Immunization Recommendations by Country 23
Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country in the Global Markets, 2014 24
Table 7: Leading Vaccines for HBV, 2014 27
Table 8: Product Profile - Fendrix 29
Table 9: Immunogenicity Profile - Fendrix 30
Table 10: Safety Profile - Fendrix 30
Table 11: Fendrix SWOT Analysis, 2014 31
Table 12: Global Sales Forecasts ($m) for Fendrix, 2012-2022 32
Table 13: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, by Country 52
Table 14: Patient Population(s) Targeted for HBV Vaccination in the Adult Market, by Country 53
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, by Country 60

1.2 List of Figures

Figure 1: HBV Structure and the Recombinant Vaccine Development Process 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...

2016-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

2016-2021 Global Hepatitis Markers Testing Market: Hospitals, Blood Banks, Public Health Labs, Commercial Labs, Physician Offices--Supplier Shares and Country Sales Segment Forecasts for 10 Immunodiagnostic and NAT Procedures

  • $ 6250
  • Industry report
  • November 2016
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...

2017-2021 Hepatitis Diagnostic Testing Market

2017-2021 Hepatitis Diagnostic Testing Market

  • $ 6250
  • Industry report
  • February 2017
  • by Venture Planning Group

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology ...


Download Unlimited Documents from Trusted Public Sources

Mental Health Statistics in the UK

  • February 2017
    82 pages
  • Mental Health  

    Hospital  

  • United Kingdom  

View report >

Tuberculosis Statistics

  • February 2017
    200 pages
  • Infectious Dise...  

    Tuberculosis  

  • United States  

    North America  

    Europe  

View report >

Hepatitis Statistics in the Netherlands

  • February 2017
    19 pages
  • Hepatitis  

  • Netherlands  

View report >

Related Market Segments :

Hepatitis

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.